◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2675

Shenzhen Edge Medical Co Ltd (2675) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-10

Shenzhen Edge Medical Co Ltd (2675) operates in the Medical Devices industry and is headquartered in Shenzhen, China with about 602 employees. Its market capitalization is roughly CNY 15 billion. In the fiscal year ended 2025-12-31, 2675 reported CNY 456M in revenue and (CNY 89M) in net income.

Shenzhen Edge Medical Co., Ltd. engages in designing, developing, manufacturing, and sale of surgical robots in Europe, and China. The company focus on surgical robots and instruments for minimally invasive surgery or MIS, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots.

Interactive charts & full statements →

2675 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-31
Total RevenueCNY 456MCNY 160MCNY 48M
Gross ProfitCNY 301MCNY 98MCNY 28M
Operating Income (EBIT)(CNY 103M)(CNY 249M)(CNY 264M)
Net Income(CNY 89M)(CNY 218M)(CNY 213M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2675 Free Cash Flow History

2675 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-31
Total AssetsCNY 1.4BCNY 1.4BCNY 1.6B
Total LiabilitiesCNY 187MCNY 101MCNY 117M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2675 viewer.

Other Companies in Medical Devices

← 2674All “0-9” companies2676 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.